Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 study

July 2, 2026 07:13 AM EDT R&DPharma Roche’s lung can­cer pill beats ri­vals in head-to-head Phase 3 study Anna Brown News Reporter Roche’s lung can­cer drug can­di­date di­vara­sib has beat­en mar­ket­ed drugs from Am­gen and Bris­tol My­ers Squibb in a head-to-head tri­al. Full da­ta haven’t yet emerged … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER